NCT01462630View on ClinicalTrials.gov

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 3, 2011

Primary Completion Date

January 2, 2019

Study Completion Date

January 12, 2021

Conditions
Adult AngiosarcomaRecurrent Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
Interventions
DRUG

pazopanib hydrochloride

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

positron emission tomography

Correlative studies

PROCEDURE

computed tomography

Correlative studies

RADIATION

fludeoxyglucose F 18

Correlative studies

Trial Locations (5)

29425

Hollings Cancer Center Medical University of South Carolina, Charleston

48109

University of Michigan, Ann Arbor

60611

Northwestern University, Chicago

77030

M D Anderson Cancer Center, Houston

19111-2497

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fox Chase Cancer Center

OTHER

NCT01462630 - Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | Biotech Hunter | Biotech Hunter